A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis

Inflammation Research

Volumn 54, Issue 1, 2005, Pages 1-9

  Miyata, S ^a   Ohkubo, Y ^a   Mutoh, S ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Adjuvant induced arthritis; Collagen induced arthritis; DMARD; Rheumatoid arthritis; Tacrolimus

Indexed keywords

CYTOKINE; INTERLEUKIN 1; LEFLUNOMIDE; METHOTREXATE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

BONE; CARTILAGE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

ANALGESICS; ANIMALS; ARTHRITIS, RHEUMATOID; CARTILAGE; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; TACROLIMUS;

EID: 15244347784     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-004-1318-5     Document Type: Review

References (81)

1. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992; 35: 729-35.
2. Yocum DE. T cells: pathogenic cells and therapeutic targets in rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 27-35.
3. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
4. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000; 51: 207-29.
5. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiotics 1987; 40: 1249-55.
6. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiotics 1987; 40: 1256-65.
7. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate. A six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 2002; 46: 2020-8.
8. Yocum DE, Furst DE, Kaine TL, Baldassare AR, Stevenson JT, Borton MA et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 3328-37.
9. Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, Sugawara S. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: A randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004; 31: 243-51.
10. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80: S40-5.
11. Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S et al. FK506 potently inhibits T cell activation induced TNF-α and IL-1β production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol 2000; 130: 1655-63.
12. Sakuma S, Kato Y, Nishigaki F, Magari K, Miyata S, Ohkubo Y et al. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int Immunopharmacol 2001; 1: 749-57.
13. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol 2003; 30: 2193-200.
14. Magari K, Miyata S, Ohkubo Y, Mutoh S. Inflammatory cytokine levels in paw tissues during development of rat collagen-induced arthritis: Effect of FK506, an inhibitor of T cell activation. Inflamm Res 2004; 53: 469-74.
15. Magari K, Nishigaki F, Sasakawa T, Ogawa T, Miyata S, Ohkubo Y at al. Anti-arthritic properties of FK506 on collagen-induced arthritis in rats. Inflamm Res 2003; 52: 524-9.
16. Sakuma S, Nishigaki F, Magari K, Ogawa T, Miyata S, Ohkubo Y et al. FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm Res 2001; 50: 509-14.
17. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S. Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: Effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflamm Res 2004; 53: 544-50.
18. Magari K, Miyata S, Ohkubo Y, Mutoh S, Goto T. Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis. Br J Pharmacol 2003; 139: 927-34.
19. Nishigaki F, Sakuma S, Ogawa T, Miyata S, Ohkubo Y, Goto T. FK506 induces chondrogenic differentiation of a clonal mouse embryonic cell line. ATDC5. Eur J Pharmacol 2002; 437: 123-8.
20. + T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur J Immunol 1994; 24: 3148-54.
21. Suttles J, Milhorn DM, Miller RW, Poe JC, Wahl LM, Stout RD. CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. J Biol Chem 1999; 274: 5835-42.
22. McAllister PT, Ellis TM. CD2 regulates T cell-dependent induction of monocyte IL-1β mRNA during anti-CD3 mitogenesis. Cell Iminunol 1996; 170: 120-6.
23. Sebbag M, Parry SL, Brennan FM, Feldmann M. 1997. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-α, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol 1997; 27: 624-32.
24. Burger D. Cell contact-mediated signaling of monocytes by stimulated T cells: a major pathway for cytokine induction. Eur Cytokine Netw 2000; 11: 346-53.
25. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989; 143: 718-26.
26. Drosos AA. Newer immunosuppressive drugs. Their potential role in rheumatoid arthritis therapy. Drugs 2002; 62: 891-907.
27. Bondeson J, Sundler R. Auranofin inhibits the induction of interleukin 1β and tumor necrosis factor α mRNA in macrophages. Biochem Pharmacol 1995; 50: 1753-9.
28. Hartman DA, Ochalski SJ, Carlson RP. The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A. Inflamm Res 1995; 44: 269-74.
29. Laufer S, Greim C, Bertsche T. An in vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs. Osteoarthr Cartilage 2002; 10: 961-7.
30. Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with IκBα degradation. Inflamm Res 2002; 51: 188-94.
31. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13: 85-94.
32. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996; 279: 1453-61.
33. Kumar S, Boehm J, Lee JC. p38 map kinases: Key signaling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717-26.
34. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum 2003; 48: 3013-22.
35. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003; 21: S2/24-S2/34.
36. Danning CL, Boumpas DT. Commonly used disease-modifying antirheumatic drags in the treatment of inflammatory arthritis: An update on mechanism of action. Clin Exp Rheumatol 1998; 16: 595-604.
37. Gutierrez-Ureña S, Molina JF, García CO, Cuéllar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 272-6.
38. Breedveld FC, Dayer J-M. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 841-9.
39. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant Int 2000; 13: 313-26.
40. Andoh TF, Burdmann EA, Bennett WM. Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Semin Nephrol 1997; 17: 34-45.
41. Billingham MEJ. Models of arthritis and the search for antiarthritic drugs. Pharmac Ther 1983; 21: 389-428.
42. Durie FH, Fava RA, Noelle RJ. Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol 1994; 73: 11-8.
43. McComb J, Gould T, Chlipala E, Sennello G, Frazier J, Kieft G et al. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: Correlation of plasma levels with efficacy. J Rheumatol 1999; 26: 1347-51.
44. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-8.
45. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis. Comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999; 42: 498-506.
46. Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998; 41: 2117-21.
47. Campbell IK, O'Donnell K, Lawlor KE, Wicks IP. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 2001; 107: 1519-27.
48. Nishikawa N, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003; 48: 2670-81.
49. Feldmann M, Maini RN. Anti-TNF α therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol 2001; 19: 163-96.
50. Szekanecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM, Haines III GK et al. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43: 1266-77.
51. Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Connolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 1993;5;298-304.
52. Van Eden W, Holoshitz J, Nevo Z, Frenkel A, Klajman A, Cohen IR. Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. Proc Natl Acad Sci USA 1985; 82: 5117-20.
53. Klareskog L, Holmdahl R, Larsson E, Wigzell H. Role of T lymphocytes in collagen II induced arthritis in rats. Clin Exp Immunol 1983; 51: 117-25.
54. Inamura N, Hashimoto M, Nakahara K, Aoki H, Yamaguchi I, Kohsaka M. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol 1988; 46: 82-90.
55. Guillemin F. Functional disability and quality-of-life assessment in clinical practice. Rheumatology 2000; 39(suppl. 1): 17-23.
56. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C et al. Function and health-related quality of life. Results from randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1870-8.
57. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis. Sensitivity and relative efficiency to detect a treatment in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000; 43: 506-14.
58. Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD et al. Improved functional ability in patients with rheumatoid arthritis - Longterm treatment with leflunomide versus sulfasalazine. J Rheumatol 2001; 28: 1983-91.
59. Scott DL, Strand V. The effects of disease-modifying anti-rheumatic drugs on health assessment questionnaire score. Lessons from the leflunomide clinical trials database. Rheumatology 2002; 41: 899-909.
60. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 1984-92.
61. Helliwell P, Howe A, Wright V Functional assessment of the hand: reproducibility, acceptability, and utility of a new system for measuring strength. Ann Rheum Dis 1987; 46: 203-8.
62. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996; 97: 2672-9.
63. 2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 1996; 184: 883-91.
64. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14.
65. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S. Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 1988; 334: 698-700.
66. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH. The pivotal role of tumour necrosis factor α in the development of inflammatory hyperalgesia. Br J Pharmacol 1992; 107: 660-4.
67. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ. Contribution of interleukin-1β to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 1995; 115: 1265-75.
68. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor α. Br J Pharmacol 1997; 121: 417-24.
69. Martin D. Interleukin-1 and tumor necrosis factor: Rheumatoid arthritis and pain. In: Cytokines and Pain. L.R. Watkins, and S.F. Maier, eds. Birkäuser, Basel, Switzerland, 1999; 205-19.
70. Gold BG. FK506 and the role of immunophilins in nerve regeneration. Mol Neurobiol 1997; 15: 285-306.
71. Avramut M, Achim CL. Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem 2003; 3: 1376-82.
72. Tang L, Ebara S, Kawasaki S, Wakabayashi S, Nikaido T, Takaoka K. FK506 enhanced oeseoblastic differentiation in mesenchymal cells. Cell Biol Int 2002; 26: 75-84.
73. Voggenreiter G, Assenmacher S, Kreuzfelder E, Wolf M, Kim M-R, Nast-Kolb D et al. Immunosuppression with FK506 increases bone induction in demineralized isogenic and xenogenic bone matrix in the rat. J Bone Miner Res 2000; 15: 1825-34.
74. Akiyama H, Fukumoto A, Shigeno C, Ito H, Mukai S, Hoshino T et al. TAK-778, a novel synthetic 3-benzothiepin derivative, promotes chondrogenesis in vitro and in vivo. Biochem Biophys Res Commun 1999; 261: 131-8.
75. Jorgensen C, Noel D, Apparailly F, Sany J. Stem cells for repair of cartilage and bone: the next challenge in osteoarthritis and rheumatoid arthritis. Ann Rheum Dis 2001; 60: 305-9.
76. Noël D, Djouad F, Jorgensen C. Regenerative medicine through mesenchymal stem cells for bone and cartilage repair. Curr Opin Investig Drugs 2002; 3: 1000-4.
77. Mi Z, Ghivizzani SC, Lechman ER, Jaffurs D, Glorioso JC, Evans CH, Robbins PD. Adenovirus-mediated gene transfer of insulin-like growth factor 1 stimulates proteoglycan synthesis in rabbit joints. Arthritis Rheum 2000; 43: 2563-70.
78. Glansbeek HL, van Beuningen HM, Vitters EL, van der Kraan PM, van den Berg WB. Stimulation of articular cartilage repair in established arthritis by local administration of transforming growth factor-β into murine knee joints. Lab Invest 1998; 78: 133-42.
79. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43: 2648-59.
80. Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology 2004; 43: 992-9.
81. McCarey DW, Capell HA, Madhok R. Tacrolimus therapy in rheumatoid arthritis. Rheumatology 2004; 43: 946-8.